References
- Amer Diabet A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32:S62–S67.
- Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi:https://doi.org/10.1038/nrendo.2017.151.
- Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–88. doi:https://doi.org/10.1152/physrev.00045.2011.
- Sabanayagam C, Banu R, Chee ML, Lee R, Wang YX, Tan G, Jonas JB, Lamoureux EL, Cheng C-Y, Klein BEK, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol. 2019;7(2):140–49. doi:https://doi.org/10.1016/S2213-8587(18)30128-1.
- Leasher JL, Bourne RRA, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, Pesudovs K, Price H, White RA, Wong TY, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39(9):1643–49. doi:https://doi.org/10.2337/dc15-2171.
- Song P, Yu J, Chan KY, Theodoratou E, Rudan I Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. J Glob Health. 2018;8(1):010803. doi:https://doi.org/10.7189/jogh.08.010803.
- Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. Jci Insight. 2017;2(14). doi:https://doi.org/10.1172/jci.insight.93751.
- Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44(4):260–77. doi:https://doi.org/10.1111/ceo.12696.
- Khan N, Paterson AD, Roshandel D, Raza A, Ajmal M, Waheed NK, Azam M, Qamar R Association of IGF1 and VEGFA polymorphisms with diabetic retinopathy in Pakistani population. Acta Diabetol. 2020;57(2):237–45. doi:https://doi.org/10.1007/s00592-019-01407-5.
- Choudhuri S, Chowdhury IH, Das S, Dutta D, Saha A, Sarkar R, Mandal LK, Mukherjee S, Bhattacharya B, et al. Role of NF-kappa B activation and VEGF gene polymorphisms in VEGF up regulation in non-proliferative and proliferative diabetic retinopathy. Mol Cell Biochem. 2015;405(1–2):265–79. doi:https://doi.org/10.1007/s11010-015-2417-z.
- Dong H, Li Q, Wang M, Wan G Association between IL-10 gene polymorphism and diabetic retinopathy. Med Sci Monit. 2015;21:3203–08.
- Tao D, Mai X, Zhang T, Mei Y. Association between the RAGE (receptor for advanced glycation end-products) −374T/A gene polymorphism and diabetic retinopathy in T2DM. Rev Assoc Med Bras (1992). 2017;63(11):971–77. doi:https://doi.org/10.1590/1806-9282.63.11.971.
- Klen J, Goricar K, Dolzan V. Genetic variability in sodium-glucose cotransporter 2 influences glycemic control and risk for diabetic retinopathy in type 2 diabetes patients. J Med Biochem. 2020;39(3):276–82.
- Han M, Dong Z, Duan H, Sun X, Zhang T, Ying M, et al. Associations of rs2300782 CAMK4, rs2292239 ERBB3 and rs10491034 ARHGAP22 with diabetic retinopathy among Chinese Hui population. DNA Cell Biol. 2020;39(3):398–403. doi:https://doi.org/10.1089/dna.2019.5027.
- Midani F, Ben Amor Z, El Afrit MA, Kallel A, Feki M, Soualmia H. The role of genetic variants (rs869109213 and rs2070744) of the eNOS gene and Bgl II in the α 2 subunit of the α 2 β 1 integrin gene in diabetic retinopathy in a Tunisian population. Semin Ophthalmol. 2019;34(5):365–74. doi:https://doi.org/10.1080/08820538.2019.1632354.
- Brandstrom H, Jonsson KB, Vidal O, Ljunghall S, Ohlsson C, Ljunggren Ö. Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun. 1998;248(3):454–57. doi:https://doi.org/10.1006/bbrc.1998.8993.
- Peng L, Zhang H, Zhou Y, Li W, Jiang P, Zhang Y, Song K. TNF-α suppression and osteoprotegerin overexpression inhibits wear debris-induced inflammation and osteoclastogenesis in vitro. Int J Artif Organs. 2015;38(10):565–71. doi:https://doi.org/10.5301/ijao.5000445.
- Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003;149(1):39–42. doi:https://doi.org/10.1530/eje.0.1490039.
- Jørgensen GM, Vind B, Nybo M, Rasmussen LM, Højlund K. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. Eur J Endocrinol. 2009;161(1):95–101. doi:https://doi.org/10.1530/EJE-09-0141.
- Mankoč Ramuš S, Kumše T, Globočnik Petrovič M, Petrovič D, Cilenšek I. SNP rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes. Biomed Res Int. 2013;2013:364073.
- Peng Y, Sheng X, Xue F. The genetic association between osteoprotegerin (OPG) gene polymorphisms and bone mineral density (BMD) in postmenopausal women: a meta-analysis (vol 51, e13507, 2018). Medicine. 2019;98(11).
- Palabiyik O, Ozdemir F, Tokuc B, Sipahi T, Kabayel DD. Association analysis between A163G and T245G gene polymorphisms of osteoprotegerin and bone mineral density in Turkish postmenopausal women. Acta Physiol. 2017;221:230–230.
- Cai Y-M, Wang J, Wang Q-W, Long X, Wang W-G, Zhang L, Zeng H-P, Wu Z-C. Association of OPG gene polymorphism with susceptibility to rheumatoid arthritis in Chinese Han. Immunol Lett. 2015;165(2):102–06. doi:https://doi.org/10.1016/j.imlet.2014.07.011.
- Yang H, Liu W, Zhou X, Rui H, Zhang H, Liu R. The association between RANK, RANKL and OPG gene polymorphisms and the risk of rheumatoid arthritis: a case-controlled study and meta-analysis. Biosci Rep. 2019;39(6). doi:https://doi.org/10.1042/BSR20182356.
- Bruhn-Olszewska B, Korzon-Burakowska A, Węgrzyn G, Jakóbkiewicz-Banecka J. Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers for Charcot arthropathy development. Sci Rep. 2017;7(1):501. doi:https://doi.org/10.1038/s41598-017-00563-4.
- Mrozikiewicz-Rakowska B, Lukawska M, Nehring P, Szymanski K, Sobczyk-Kopciol A, Krzyzewska M, Maroszek P, Ploski R, Czupryniak L. Genetic predictors associated with diabetic retinopathy in patients with diabetic foot. Pol Arch Internal Med Polskie Archiwum Medycyny Wewnetrznej. 2018;128:35–42.
- Ramus SM, Kumse T, Petrovic MG, Petrovic D, Cilensek I. SNP rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes. Biomed Res Int. 2013;2013.
- Priščáková P, Minárik G, Repiská V. Candidate gene studies of diabetic retinopathy in human. Mol Biol Rep. 2016;43(12):1327–45. doi:https://doi.org/10.1007/s11033-016-4075-y.
- Pitocco D, Zelano G, Gioffre G, Di Stasio E, Zaccardi F, Martini F, Musella T, Scavone G, Galli M, Caputo S, et al. Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic Charcot neuroarthropathy. Diabetes Care. 2009;32(9):1694–97. doi:https://doi.org/10.2337/dc09-0243.
- Nehring P, Mrozikiewicz‑Rakowska B, Sobczyk‑Kopcioł A, Makowski A, Krasnodębski P, Płoski R, Broda G, Karnafel W. Osteoprotegerin gene rs2073617 and rs3134069 polymorphisms in type 2 diabetes patients and sex-specific rs2073618 polymorphism as a risk factor for diabetic foot. Polskie Archiwum Medycyny Wewnetrznej-Pol Arch Internal Med. 2013;123(4):176–82. doi:https://doi.org/10.20452/pamw.1684.
- Mrozikiewicz-Rakowska B, Maroszek P, Nehring P, Sobczyk-Kopciol A, Krzyzewska M, Kaszuba AM, Lukawska M, Chojnowska N, Kozka M, Bujalska-Zadrozny M, et al. Genetic and environmental predictors of chronic kidney disease in patients with type 2 diabetes and diabetic foot ulcer: a pilot study. J Physiol Pharmacol. 2015;66:751–61.
- Chang YH, Lin K-D, He S-R, Hsieh M-C, Hsiao J-Y, Shin S-J. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy. Metabolism. 2011;60(8):1064–69. doi:https://doi.org/10.1016/j.metabol.2010.11.002.
- Kim -H-H, Shin HS, Kwak HJ, Ahn KY, Kim J-H, Lee HJ, Lee M-S, Lee ZH, Koh GY, et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3ʹ-kinase/Akt signal transduction pathway. FASEB J. 2003;17(14):1–17. doi:https://doi.org/10.1096/fj.03-0215fje.